Erratum: Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells (BioMed Research International (2014) 2014 (384121) DOI: 10.1155/2014/384121);Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Huang, Suning ^a   He, Rongquan ^a   Rong, Minhua ^b   Dang, Yiwu ^a   Chen, Gang ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CETUXIMAB; ERLOTINIB; GEFITINIB; MICRORNA 146A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RESORUFIN; STAT5 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; MICRORNA; MIRN146 MICRORNA, HUMAN; MONOCLONAL ANTIBODY;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVITY; FLUORESCENCE MICROSCOPY; FLUOROMETRY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPECTROPHOTOMETRY; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HEPG2 CELL LINE; LIVER NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DRUG SYNERGISM; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICRORNAS; TREATMENT OUTCOME;

EID: 84901766623     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2020/9375214     Document Type: Erratum

References (50)

1. Kudo M., Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy. Oncology 2011 81 supplement 1 1 10 2-s2.0-84855313808 10.1159/000333252
2. Meguro M., Mizuguchi T., Kawamoto M., Hirata K., The molecular pathogenesis and clinical implications of hepatocellular carcinoma. International Journal of Hepatology 20112011 2011 8 818672 10.4061/2011/818672
3. Yamazaki K., Masugi Y., Sakamoto M., Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor- β signaling in hepatocarcinogenesis. Digestive Diseases 2011 29 3 284 288 2-s2.0-80051768100 10.1159/000327560
4. Zemel R., Issachar A., Tur-Kaspa R., The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma. Clinics in Liver Disease 2011 15 2 261 279 2-s2.0-79959304448 10.1016/j.cld.2011.03.001
5. Vertemati M., Moscheni C., Petrella D., Lamperti L., Cossa M., Gambacorta M., Goffredi M., Vizzotto L., Morphometric analysis of hepatocellular nodular lesions in HCV cirrhosis. Pathology Research and Practice 2012 208 4 240 244 2-s2.0-84859444009 10.1016/j.prp.2012.02.007
6. Abdo A. A., Al-Ahdal M. N., Khalid S. S., IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatology International 2013 7 533 538
7. Feng H., Zhang J., Li X., Chen W. N., HBX-Mediated migration of HBV-replicating HepG2 cells: insights on development of hepatocellular carcinoma. Journal of Biomedicine and Biotechnology 2009 2009 6 2-s2.0-70350026318 10.1155/2009/930268 930268
8. Hu L., Chen G., Yu H., Qiu X., Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatology International 2010 4 1 423 432 2-s2.0-77949658391 10.1007/s12072-010-9164-8
9. Chen G., Luo D., Expression of decoy receptor 3 in liver tissue microarrays. National Medical Journal of India 2008 21 6 275 278 2-s2.0-65349154749
10. Chen G., Dang Y.-W., Luo D.-Z., Feng Z.-B., Tang X.-L., Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study. Oncology Research 2008 17 4 183 189 2-s2.0-51049117490 10.3727/096504008785114138
11. Chen G., Luo D. Z., Liu L., Feng Z. B., Guo F., Li P., Hepatic local micro-environmental immune status in hepatocellular carcinoma and cirrhotic tissues. West Indian Medical Journal 2006 55 6 403 408 2-s2.0-34249672213 (Pubitemid 46824626)
12. Chen G., Luo D., Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Upsala Journal of Medical Sciences 2008 113 3 297 304 2-s2.0-56749136445
13. Yang M., Chen G., Dang Y., Luo D., Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Upsala Journal of Medical Sciences 2010 115 4 232 237 2-s2.0-77958530304 10.3109/03009734.2010.516410
14. Ruan Z. P., Xu R., Lv Y., Tian T., Wang W. J., Guo H., Nan K. J., PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib. Oncology Research 2012 20 2-3 113 121
15. Aravalli R. N., Steer C. J., Cressman E. N. K., Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008 48 6 2047 2063 2-s2.0-58149376548 10.1002/hep.22580
16. Philip P. A., Mahoney M. R., Allmer C., Thomas J., Pitot H. C., Kim G., Donehower R. C., Fitch T., Picus J., Erlichman C., Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. Journal of Clinical Oncology 2005 23 27 6657 6663 2-s2.0-27244447373 10.1200/JCO.2005.14.696 (Pubitemid 46190260)
17. Tang W., Weng S., Zhang S., Direct interaction between surface beta1, 4-galactosyltransferase 1 and epidermal growth factor receptor (EGFR) inhibits EGFR activation in hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2013 434 449 454
18. Sanoff H. K., Bernard S., Goldberg R. M., Morse M. A., Garcia R., Woods L., Moore D. T., O'Neil B. H., Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma. Gastrointestinal Cancer Research 2011 4 3 78 83 2-s2.0-80053012405
19. Asnacios A., Fartoux L., Romano O., Tesmoingt C., Louafi S S., Mansoubakht T., Artru P., Poynard T., Rosmorduc O., Hebbar M., Taieb J., Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008 112 12 2733 2739 2-s2.0-46049097410 10.1002/cncr.23489 (Pubitemid 351969218)
20. Zhu A. X., Stuart K., Blaszkowsky L. S., Muzikansky A., Reitberg D. P., Clark J. W., Enzinger P. C., Bhargava P., Meyerhardt J. A., Horgan K., Fuchs C. S., Ryan D. P., Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007 110 3 581 589 2-s2.0-34547102484 10.1002/cncr.22829 (Pubitemid 47106147)
21. Huether A., Höpfner M., Baradari V., Schuppan D., Scherübl H., EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochemical Pharmacology 2005 70 11 1568 1578 2-s2.0-27544497021 10.1016/j.bcp.2005.09.007 (Pubitemid 41540350)
22. Thomas M. B., Morris J. S., Chadha R., Iwasaki M., Kaur H., Lin E., Kaseb A., Glover K., Davila M., Abbruzzese J., Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. Journal of Clinical Oncology 2009 27 6 843 850 2-s2.0-60849124241 10.1200/JCO.2008.18.3301
23. Zhu A. X., Blaszkowsky L. S., Ryan D. P., Clark J. W., Muzikansky A., Horgan K., Sheehan S., Hale K. E., Enzinger P. C., Bhargava P., Stuart K., Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology 2006 24 12 1898 1903 2-s2.0-33646351795 10.1200/JCO.2005.04.9130 (Pubitemid 46638989)
24. Faivre S., Raymond E., Boucher E., Douillard J., Lim H. Y., Kim J. S., Zappa M., Lanzalone S., Lin X., DePrimo S., Harmon C., Ruiz-Garcia A., Lechuga M. J., Cheng A. L., Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. The Lancet Oncology 2009 10 8 794 800 2-s2.0-67651165187 10.1016/S1470-2045(09)70171-8
25. Palmer D. H., Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 2008 359 23 2498 2499 2-s2.0-57349122313
26. Copur M. S., Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 2008 359 23 2498 2499 2-s2.0-57349191046
27. Spinzi G., Paggi S., Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 2008 359 23 2498 2499 2-s2.0-57349185934
28. Llovet J. M., di Bisceglie A. M., Bruix J., Kramer B. S., Lencioni R., Zhu A. X., Sherman M., Schwartz M., Lotze M., Talwalkar J., Gores G. J., Design and endpoints of clinical trials in hepatocellular carcinoma. Journal of the National Cancer Institute 2008 100 10 698 711 2-s2.0-44449085884 10.1093/jnci/djn134
29. Llovet J. M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.-F., De Oliveira A. C., Santoro A., Raoul J.-L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T. F., Galle P. R., Seitz J.-F., Borbath I., Häussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J., Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 2008 359 4 378 390 2-s2.0-47949116252 10.1056/NEJMoa0708857
30. Augello C., Vaira V., Caruso L., Destro A., Maggioni M., Park Y. N., Montorsi M., Santambrogio R., Roncalli M., Bosari S., MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver International 2012 32 5 772 782 2-s2.0-84859445143 10.1111/j.1478-3231.2012.02795.x
31. Negrini M., Gramantieri L., Sabbioni S., Croce C. M., microRNA involvement in hepatocellular carcinoma. Anti-Cancer Agents in Medicinal Chemistry 2011 11 6 500 521 2-s2.0-79959288902
32. Sato F., Hatano E., Kitamura K., Myomoto A., Fujiwara T., Takizawa S., Tsuchiya S., Tsujimoto G., Uemoto S., Shimizu K., MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan criteria. PLoS ONE 2011 6 1 2-s2.0-79551507191 10.1371/journal.pone. 0016435 e16435
33. Diao S., Zhang J.-F., Wang H., He M.-L., Lin M. C.-M., Chen Y., Kung H.-F., Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma. Proteomics 2010 10 20 3723 3731 2-s2.0-78649403064 10.1002/pmic.201000050
34. Burchard J., Zhang C., Liu A. M., Poon R. T. P., Lee N. P. Y., Wong K.-F., Sham P. C., Lam B. Y., Ferguson M. D., Tokiwa G., Smith R., Leeson B., Beard R., Lamb J. R., Lim L., Mao M., Dai H., Luk J. M., MicroRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Molecular Systems Biology 2010 6, article 402 2-s2.0-77956249298 10.1038/msb.2010.58
35. Rong M., He R., Dang Y., Chen G., Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Upsala Journal of Medical Sciences 2014 119 1 19 24
36. Chen G., Kronenberger P., Teugels E., De Grève J., Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. Biological Procedures Online 2011 13 1, article 1 2-s2.0-84858129696 10.1186/1480-9222-13-1
37. Chen G., Kronenberger P., Teugels E., Umelo I. A., De Grève J., Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Medicine 2012 10, article 28 2-s2.0-84858595433 10.1186/1741-7015-10-28
38. Chen G., Kronenberger P., Teugels E., Umelo I. A., De Greve J., Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Biochemical and Biophysical Research Communications 2013 431 623 629
39. Chen G., Kronenberger P., Umelo I. A., Teugels E., De Grève J., Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Analytical Biochemistry 2010 398 2 266 268 2-s2.0-77649190426 10.1016/j.ab.2009.11.034
40. Chen G., Noor A., Kronenberger P., Teugels E., Umelo I. A., De Grève J., Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS ONE 2013 8 e59708
41. Chen G., Umelo I. A., Lv S., miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS ONE 2013 8 e60317
42. Chen G., Rong M., Luo D., TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell. Pathology Research and Practice 2010 206 9 631 641 2-s2.0-77956011978 10.1016/j.prp.2010. 05.011
43. Dang Y., Luo D., Rong M., Chen G., Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS ONE 2013 8 e61054
44. Rong M., Chen G., Dang Y., Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer 2013 13, article 21
45. Koivusalo R., Krausz E., Helenius H., Hietanen S., Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Molecular Pharmacology 2005 68 2 372 382 2-s2.0-23044502867 10.1124/mol.105.011189 (Pubitemid 41058301)
46. Chou T.-C., Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews 2006 58 3 621 681 2-s2.0-33748794547 10.1124/pr.58.3.10 (Pubitemid 44403686)
47. Li Y., VandenBoom T. G. II, Wang Z., Kong D., Ali S., Philip P. A., Sarkar F. H., miR-146a suppresses invasion of pancreatic cancer cells. Cancer Research 2010 70 4 1486 1495 2-s2.0-76749152907 10.1158/0008-5472.CAN-09-2792
48. Xu B., Wang N., Wang X., Tong N., Shao N., Tao J., Li P., Niu X., Feng N., Zhang L., Hua L., Wang Z., Chen M., MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate 2012 72 1171 1178 2-s2.0-82755167769 10.1002/pros.22466
49. Bhaumik D., Scott G. K., Schokrpur S., Patil C. K., Campisi J., Benz C. C., Expression of microRNA-146 suppresses NF- B activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008 27 42 5643 5647 2-s2.0-52149102044 10.1038/onc.2008.171
50. Mei J., Bachoo R., Zhang C.-L., MicroRNA-146a inhibits glioma development by targeting Notch1. Molecular and Cellular Biology 2011 31 17 3584 3592 2-s2.0-80052319304 10.1128/MCB.05821-11